Biocardia Inc (BCDA) - News Archive

BioCardia, Inc. (Nasdaq: BCDA), a frontrunner in cellular and cell-derived therapeutics aimed at addressing cardiovascular and pulmonary diseases, continues to make significant strides in the field of cardiac care. The...

BioCardia Successfully Closes Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq RulesSUNNYVALE, Calif. Sept. 09, 2024 - BioCardia, Inc. Nasdaq: BCDA, a globally renowned leader in cellular and cell-...

In a strategic move that reflects the company’s commitment to advancing its innovative solutions in cellular therapeutics, BioCardia, Inc. (Nasdaq: BCDA), has announced the pricing of an upsized public offering. The off...

In a significant development for cardiology and innovative medical technology, BioCardia, Inc. a burgeoning leader in cellular and cell-derived therapeutics, announced on August 29, 2024, that its Morph DNA Steerable In...

In a pivotal move for cardiac therapy development, the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the CardiAMP Heart Failure II clinical trial protocol developed by BioCardia. This...

BioCardia, Inc., a prominent figure in cellular therapeutics, has recently announced the commencement of patient enrollment in a pivotal Phase 3 trial assessing its innovative CardiAMP cell therapy. This landmark resear...

In recent weeks, BioCardia Inc., a developer of cellular and cell-derived therapeutics for cardiovascular diseases, has been making significant progress in the field of innovative therapies. From receiving a United Stat...

In a noteworthy collaboration, CellProthera and BioCardia have achieved success in their Phase II trial of ProtheraCytes for the treatment of Acute Myocardial Infarction (AMI). This breakthrough brings hope for improved...

BioCardia, Inc., a leading developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced its intent to undergo a reverse stock split at a ratio of 1 post-split sha...

BioCardia, a prominent biotechnology company specializing in cell therapy interventions for cardiovascular disorders, has recently unveiled the primary endpoint results of their CardiAMP Cell Therapy trial. The trial ai...

BioCardia Advances Promising Cell Therapy Trials for Cardiovascular Conditions with Encouraging Results and Japanese Approval in SightSUNNYVALE, Calif., Dec. 19, 2023 - BioCardia, Inc. Nasdaq: BCDA, a leading developer...

I. Heart failure remains a major global health concern, associated with significant morbidity and mortality rates. The limited treatment options available for this condition have prompted BioCardia, a leading biotechnol...

In a groundbreaking move for the field of regenerative medicine, BioCardia, a leader in cardiovascular therapies, has received approval from the Centers for Medicare & Medicaid Services (CMS) to provide reimbursement co...

SUNNYVALE, Calif., March 04, 2024 - BioCardia, Inc. (Nasdaq: BCDA), a leading biotechnology company specializing in late-stage cell therapy interventions for cardiovascular disorders, has announced positive interim resu...

BioCardia, a leading biotechnology company dedicated to advancing cell therapy interventions for cardiovascular disorders, recently announced the activation of its highly anticipated CardiAMP Heart Failure II Phase 3 Pi...

Sunnyvale-based company BioCardia, Inc. made a significant leap in the arena of cardiovascular and pulmonary disease therapeutics recently, by administering its maiden dosage in the CardiALLO Allogenic Mesenchymal Cell...

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesBioCardia, Inc. (Nasdaq: BCDA), a renowned developer of cellular and cell...